These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 19831836

  • 1. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.
    De la Gándara J, San Molina L, Rubio G, Rodriguez-Morales A, Hidalgo Borrajo R, Burón JA.
    Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836
    [Abstract] [Full Text] [Related]

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 3. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [Abstract] [Full Text] [Related]

  • 4. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.
    Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.
    Curr Med Res Opin; 2010 Mar; 26(3):501-9. PubMed ID: 20014981
    [Abstract] [Full Text] [Related]

  • 5. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [Abstract] [Full Text] [Related]

  • 6. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [Abstract] [Full Text] [Related]

  • 7. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ, Woolson SL, Hamer RM.
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [Abstract] [Full Text] [Related]

  • 8. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [Abstract] [Full Text] [Related]

  • 9. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F, Schreiner A, Thomas P, Sherif T.
    Clin Drug Investig; 2012 Apr 01; 32(4):267-79. PubMed ID: 22339430
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.
    Int Clin Psychopharmacol; 2013 Jul 01; 28(4):164-70. PubMed ID: 23587986
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L.
    Int Clin Psychopharmacol; 2010 May 01; 25(3):149-54. PubMed ID: 20305567
    [Abstract] [Full Text] [Related]

  • 12. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.
    J Psychopharmacol; 2005 Sep 01; 19(5 Suppl):5-14. PubMed ID: 16144781
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug 01; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 14. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, Burger H.
    J Clin Psychopharmacol; 2008 Dec 01; 28(6):625-30. PubMed ID: 19011430
    [Abstract] [Full Text] [Related]

  • 15. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.
    Taylor DM, Young CL, Mace S, Patel MX.
    J Clin Psychiatry; 2004 Aug 01; 65(8):1076-83. PubMed ID: 15323592
    [Abstract] [Full Text] [Related]

  • 16. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.
    Int Clin Psychopharmacol; 2014 Sep 01; 29(5):279-87. PubMed ID: 24583566
    [Abstract] [Full Text] [Related]

  • 17. One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.
    Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.
    Clin Schizophr Relat Psychoses; 2012 Jul 01; 6(2):61-8. PubMed ID: 22776632
    [Abstract] [Full Text] [Related]

  • 18. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series.
    Se Hyun Kim, Dong Chung Jung, Yong Min Ahn, Yong Sik Kim.
    J Psychopharmacol; 2010 Jul 01; 24(7):981-6. PubMed ID: 19942641
    [Abstract] [Full Text] [Related]

  • 19. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, Risperidone Long-Acting Trial Investigators (R-LAI).
    Hum Psychopharmacol; 2009 Oct 01; 24(7):574-83. PubMed ID: 19790173
    [Abstract] [Full Text] [Related]

  • 20. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A.
    J Clin Psychiatry; 2012 Sep 01; 73(9):1224-33. PubMed ID: 22938760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.